Canaccord is Bullish on Canopy Growth Corporation (CGC)

Canopy Growth Corporation (NASDAQ:CGC) is one of the

11 Best Marijuana Stocks to Buy Right Now.

On March 27, 2026, Canaccord started coverage of Canopy Growth Corporation (NASDAQ:CGC) with a Buy rating and a price target of C$2.00. The company is regarded as a major cannabis company that operates in key worldwide adult-use and medical markets while creating and selling a diverse product portfolio. The analyst stated that the company is transitioning from an asset-light, third-party supply strategy to an asset-right, in-house supply model in an attempt to boost its worldwide competitiveness.

On March 16, 2026, Canopy Growth Corporation (NASDAQ:CGC) announced the completion of its acquisition of MTL Cannabis, resulting in one of Canada’s leading medical cannabis firms in terms of sales. The corporation stated that the transaction strengthens its Canadian infrastructure, expands its high-quality flower supply, and supports worldwide growth, notably in Europe. Management anticipates roughly $10 million in run-rate synergies within 18 months while integrating MTL’s promising operations to support a target of positive adjusted EBITDA in fiscal 2027.

Canopy Growth Corporation (NASDAQ:CGC) produces, sells, and distributes cannabis and products derived from cannabinoids for both medical and recreational use. The company operates in the following segments: Canada Cannabis, International Markets Cannabis, Storz and Bickel, This Works, and Other.

While we acknowledge the potential of CGC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.